Jul 30 2012
Neurotez, Inc. today announced the grant of U.S. Patent number
8,227,408 by the United States Patent and Trademark Office
covering the company's lead product candidate, Leptin. The
patent protects use of the hormone Leptin for treating a progressive
cognitive disease, disorder or condition, such as Alzheimer's disease
(AD), resulting from accumulation of an amyloid peptide or for improving
resilience of cognitive function by modulating the accumulation of the
amyloid peptide in brain.
Compelling preclinical in vitro data and in vivo and
interventional studies, along with human epidemiological studies,
suggest that Leptin can be a promising therapy for the treatment of
Alzheimer's disease. It is well documented that brain
lipids are intricately involved in amyloid beta-related pathogenic
pathways in the development of Alzheimer's disease. Leptin may have a
physiologic role as a liporegulatory hormone for neural cells, and
several molecular targets have been identified related to metabolic
pathways that mediate Leptin's action. Patent issuance comes as Neurotez
completes GMP manufacturing of recombinant Leptin and prepares for
IND-enabling studies.
"This kind of innovation ignites tremendous excitement for the
development of new therapeutic modalities for this devastating
disorder," said Nikolaos Tezapsidis, President & CEO of Neurotez, Inc.
"The uniqueness of our therapy is that we are dealing with the
replacement of an endogenous pluripotent hormone, that we have shown it
improves cognition, and ameliorates pathobiology".
"The issuing of a patent for using Leptin as an agent to prevent
pathologic amyloidogenesis is an exciting development for the
languishing field of Alzheimer's. Leptin has been established to play an
important role in controlling the formation of beta-amyloid plaques and
preventing tau hyper-phosphorylation. Thus
using Leptin, particularly in at-risk individuals who are
Leptin-deficient, will provide a treatment and prevention strategy for
Alzheimer's disease. We are poised to initiate the clinical
studies to test that," said Dr. Wes Ashford, Clinical Professor
(affiliated) at Stanford University, Senior Research Scientist at VA
Palo Alto and acting CMO at Neurotez.
"New approaches to treating Alzheimer's Disease are desperately
needed. Leptin's dual action mechanism (targeting abeta and
tau) may provide an advantage over therapies with single mechanism, says
Lex Van der Ploeg", CSO at Rhythm and Director at Neurotez.
About the patent, Dr George Perry, Dean at the University of Texas
at San Antonio and Director at Neurotez, said:
"Leptin-based therapy focuses on a number of highly successful studies
showing metabolic alteration is at the root of Alzheimer's
disease"
Source: Neurotez